[1] Su S, He K, Li J, et al. Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study. Tumour Biol, 2015, 36: 4627-4632.
[2] Weber A, O'Connor T, Heikenwalder M. Next generation of preclinical liver cancer models. Clin Cancer Res, 2015,19:4254-4256.
[3] Gao W, Wang W, Yao S, et al. Highly sensitive detection of multiple tumor markers for lung cancer using gold nanoparticle probes and microarrays. Analytica Chimica Acta, 2017, 958:77-84.
[4] Lu Q, Xue LY, Wang WP, et al. Dynamic enhancement pattern of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: the correlation with cirrhosis and tumor size. Abdom Imaging, 2015, 6:1558-1566.
[5] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志, 2017, 16:705-720.
[6] 中华医学会肝病学分会. 慢性乙型肝炎诊断标准(2015年版). 中西医结合肝病杂志, 2015, 25:384-384.
[7] Toyoda H, Kumada T, Nakano S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer, 2015,5:957-963.
[8] Chotipanich C, Kunawudhi A, Promteangtrong C, et al. Diagnosis of hepatocellular carcinoma using C11 choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT. Asian Pac J Cancer P, 2016, 7:3569.
[9] 张煜, 周静, 李明星. 超声造影在肝脏局灶性病变良恶性诊断中的临床价值. 世界华人消化杂志, 2015,23:272-277. |
